Freiburg, Germany, January 18, 2011:
Centogene Holding AG (formerly Arcensus AG), parent company of a group of
diagnostic laboratories, announced today that Michael Schlenk, former CEO of
ProBioGen AG joined the management as Chief Executive Officer effective
January 2011. He also invested and became a major shareholder. The diagnostic
laboratories, operated under the name of Centogene™, are an internationally
active global leader in the field of molecular diagnostics for Rare Diseases.
In addition to many years as management consultant in the area of technology
transfer Michael Schlenk has more than 20 years of international life science
experience. Before he successfully sold ProBioGen AG, a Biotechnology
company from Berlin, in 2010 to the Egyptian healthcare company Minapharm, he
worked in Brazil, Austria, the US, Thailand, Switzerland for multinational
companies like Abbott and Novartis (formerly Sandoz) as President, General
Manager and Area Manager. He graduated as Diplom-Kaufmann from the
University of Hamburg, Germany and later earned his M.B.A. Degree from
University of Bradford Management Centre, U.K.
The group of companies, financed entirely without venture capital, generates a
strong cash flow from a rapidly increasing diagnostics business in the field of
Rare Diseases. The companies, with active laboratories in Rostock, Vienna and
Freiburg are offering the largest number of different genetic analyses worldwide.
Speed to adapt the organisation and prepare for systematic growth maintaining
highest level of quality standards are key drivers for continued success.
Besides his responsibilities for the overall corporate development Michael
Schlenk will actively drive Centogene’s international expansion through
partnerships and collaborations.
“With the addition of Michael Schlenk we will strengthen our team and prepare
Centogene for the next stage of development to expand beyond todays focus on
Rare Diseases” commented Prof. Dr. Arndt Rolfs, founder and Head of the
Supervisory Board, professor of Neurology and Psychiatry at the University of
Rostock and head of the Albrecht-Kossel-Institute for Neuroregeneration, both
Rostock, Germany.
